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nal, adrenal and splenic metastases are known examples in
melanoma patients which can lead to signs of obstruction,
bleeding and/or pain and good palliation has been described
in these patients [4–6]. Also patients with metastases that may
cause significant symptoms before the patient dies of the dis-
ease might be candidates for palliative surgery. This requires
considerable judgement about whether the potential benefits
of the proposed surgery outweigh the risks in the individual
patient. In this situation the surgeon is trying to protect the
quality of life with minimal morbidity and no mortality of the
procedure. This difficult decision requires knowledge of the
biology of the disease and clinical performance of the patient
and is often made in multidisciplinary teams where medical
oncologists and radiotherapists are also involved.
Another reason to perform surgery in patients with stage IV
melanoma is to aim for a potentially curative resection. This
option is not often possible and results may reflect a more
favourable biology of the disease, rather than just an indepen-
dent therapeutic benefit of the surgical procedure. However,
several studies have been presented demonstrating 5-year sur-
vival rates between 20 and 30% in selected patients with com-
pletely resected metastases [7, 8]. Unfortunately, most pub-
lished data for metastasectomy are from single-institutional
series and comparison between different reports is difficult.
Morton et al. have reported the results of a multicentre ran-
domised trial in stage IV patients who underwent complete
surgical resection [9]. Patients in this trial were randomised 
to receive adjuvant onamelatucel-L (Canvaxin®) or placebo. 
Although the trial was stopped after an interim analysis be-
cause no effect was demonstrated of the studied drug, impor-
tant observations could be made. First, selection of patients
for surgery in stage IV melanoma is essential, because only
patients with 3 or fewer visceral sites who could be treated
with complete surgical resections could enter this trial. Sec-
ond, treatment was uniformly performed in all participating
In this issue of ONKOLOGIE, Tomov et al. [1] describe a young
patient with stage IV melanoma treated with multiple surgical
resections of metastatic disease leading to an apparent cure. In
daily practice, the majority of stage IV melanoma patients pre-
sent with multiple unresectable metastatic lesions and survival
is generally poor, with 3-year overall survival rates of approxi-
mately 15% [2]. There is no systemic therapy for these pa-
tients that can be considered standard. In spite of response
rates of up to 50% with some biochemotherapy regimens, su-
periority in terms of survival has never been demonstrated
over single or polychemotherapeutic regimens, which by
themselves have not been proven to be superior to treatment
with dacarbazine (DITC) alone [3]. So the crucial question is
how do we identify patients that may benefit from a surgical
approach? Clearly the answer is by selecting out patients with
the right biology. This biology may be characterised by the
presence of oligometastatic disease and we should base our
decisions on site(s) and number of the metastases, the pres-
ence or absence of certain biomarkers, and a history of slow
versus rapid progression of the patients’ disease. The patient
in this case report is one of numerous, highly selected patients
reported in the literature who benefit from an aggressive sur-
gical approach in metastasised melanoma patients. 
In general, the two major reasons to perform surgery in stage
IV melanoma patients are palliation and cure. Palliation is
considered for patients who have surgically accessible metas-
tases that are symptomatic and negatively influencing the
quality of life. The value of surgery for palliation is vastly un-
derestimated. Unfortunately many opportunities to achieve
local control are missed and systemic therapy or radiation
therapy is given in situations where a relatively simple surgical
procedure would have provided the simplest and quickest so-
lution. Especially cutaneous, subcutaneous and distant lymph
node metastases can cause local problems that can easily and
most effectively be dealt with surgically. But also gastrointesti-
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centres with minimal morbidity and mortality and an unprece-
dented 5-year survival of approximately 40% have been
demonstrated in the overall study group of 496 patients. It is
clear that these survival percentages are the result of multiple
selection procedures. But at the same time it must be recog-
nized that an aggressive surgical approach in stage IV patients
is justified provided selection is carried out properly [3].
So, what then are the tools to select successfully those patients
that may benefit most from surgery? Established diagnostic
modalities for initial staging include patient history, physical
examination, chest X-ray, abdominal ultrasound or computed
tomography (CT) and magnetic resonance imaging (MRI).
Whether positron emission tomography (PET) has a role in
improving staging remains to be defined in prospective trials,
but results are promising [10]. Prognosis depends on the initial
site of the metastases because distant skin and subcutaneous
lesions (M1a), pulmonary metastases (M1b) and visceral
metastases (M1c) have significantly different 1-year survival
rates of 59, 57 and 41%, respectively [2]. However, it is impor-
tant to realise that after 2 and 5 years survival is similar in
these different groups and is less than 20 and 5%, respectively.
Several factors have been identified as important for progno-
sis such as serum lactate dehydrogenase (LDH) which charac-
terises poor prognosis in patients when levels are elevated [2].
Also serum 5-S-CD and S-100B protein levels have been
demonstrated to be useful to monitor the clinical course and
prognosis of patients with malignant melanoma [11]. Essner
et al. have described the largest series of 1,574 patients under-
going surgery for metastatic melanoma. They have identified
an earlier primary tumour stage (stage I vs. II), the absence of
intervening stage III metastases, solitary metastases and long
(>36 months) disease-free interval as predictive of survival
[12]. So generally, young patients in a good clinical condition
with minimal or solitary metastatic disease reflected by nor-
mal levels of LDH and long interval between resection of the
primary melanoma and presentation of the metastatic disease
are good candidates for potentially curative surgical resections
in stage IV melanoma patients. The case report presented 
by Tomov et al. [1] demonstrates that even repetitive surgical
procedures can be possible in this situation with a curative 
intent.
A word of caution at the end seems appropriate. The use of
aggressive surgical procedures in all stage IV melanoma pa-
tients should be tempered with the knowledge that incomplete
resections put patients at increased risk without any proven
survival benefit. The ideal therapeutic approach for melanoma
patients with (limited) stage IV disease would be complete
metastasectomy followed by an effective adjuvant therapy,
which remains to be identified. This should be the strategy to
focus on for medical and surgical oncologists to work together
and improve long-term survival in this clinically difficult group
of patients.
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